Member Info for bigAl67

Genedrive announced on the 20th December 2023, via RNS , that they had received initial orders for MT-RNR1 products from France, Austria, Greece, Saudi Arabia, Turkey and the Netherlands.

The initial orders will support genedrive's international distribution partners in ''promotion and in-country evaluation activities ''in their respective countries, to provide more extensive access to this life-changing test.

So clearly these orders were sent to support ''In Country Evaluation'' in their respective Countries !!

Hi Eureka,

A very good post, thank you for posting - I would just question the 2nd Negative you mention though:-

Negatives:

''2)Sales in the USA: CYP2C19 testing has been in place in the USA for around 7 years so there are already many established suppliers for the company to compete with.''

In the USA:-

''Stuart Scott, director of Stanford's Clinical Genomics Laboratory said Lab Results in weeks is Not helpful'' - They want results in Hours Not Weeks !!!

''Stuart Scott, director of Stanford's Clinical Genomics Laboratory, said that Schwartz first proposed instituting CYP2C19 testing almost two years ago.''

"It took us some time to think through the trends and the platform, but that ultimately led us to Genomadix last summer when the FDA approved their instrument," Scott said.

''Although Stanford's neurologists have had access to genetic testing prior to this, ordering a 2C19 test from an outside lab could take weeks.''

My take on the above comments from Stuart Scott is that they have been looking for a faster CYP2C19 Test for years prior to coming across the Genomadix Cube POC Test last summer - So the Quickest and Best Test they have in the USA currently is the Genomadix Cube, and NICE have just stated that our Test should be used in preference to the Genomadix Cube, in the UK - Therefore I do not see that there are many established suppliers in the USA, for our company to compete with ?.'' In fact I see our only competitor is the Genonadix Cube - And Our CYP2C19 POC Test is superior to the Genomadix Cube POC Test - And I see this as a Positive, not as a Negative ?!!!

LOL - It does not matter whether the UK Build another Lab/More Labs - They will still be too slow to supply Test Results - Patients are Not in Beds in the Labs, they are in Beds in Hospitals throughout England and the UK, and just as Stuart Scott, director of Stanford's Clinical Genomics Laboratory said Lab Results in weeks is Not helpful - They want results in Hours Not Weeks !!!

NICE have said that If Lab Tests are Not available (ie Take too long)

NICE have stated:-

. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

. Evidence from studies provided by the company suggests that the Genedrive CYP2C19 ID Kit works well. It can detect more CYP2C19 alleles than the Genomadix Cube point-of-care test. It also:

does not need a freezer to store reagents

is cheaper per test than laboratory tests and the Genomadix Cube.

. There are likely to be considerable barriers to implementing laboratory-based testing for everyone who has had an ischaemic stroke or a TIA. If laboratory-based testing is not available, ''or it will take a long time to develop capacity to provide it'', then point-of-care tests could be used. So, the Genedrive CYP2C19 ID Kit should be used when laboratory-based testing is not available.

New York Clinicians:-

Strokes are a leading cause of adult disability in the US, Schwartz said, so the ability to prevent them in patients presenting with TIA is crucial.

Stuart Scott, director of Stanford's Clinical Genomics Laboratory, said that Schwartz first proposed instituting CYP2C19 testing almost two years ago.

Although Stanford's neurologists have had access to genetic testing prior to this, ordering a 2C19 test from an outside lab could take weeks.

"That's not particularly helpful because this high-risk period is a few days to a few weeks, so we really would like to get that result within hours to help make this decision," said Schwartz.

This will be No different in the UK and the ROW - Results needed in Hours - Not Days.

Genedrivegenedrive

4,007 followers4,007 followers

1w • 1 week ago

NICE has recommended the Genedrive CYP2C19 ID Kit for NHS use!

The development of the product was part of the DEVOTE programme in collaboration with MFT Research and Innovation and The University of Manchester of Manchester, led by Dr John McDermott and Professor William Newman.

Gino Miele, genedrive CEO said:

“The collaboration of our company with the research and clinical team at MFT is a shining example of the NHS collaborating with a commercial company, from early product development through to clinical validation in real-world settings, to deliver real improvements in patient outcomes in a cost-effective way. We are delighted with the positive recommendation from NICE and the success of the multi-disciplinary team collaboration under DEVOTE. We look forward to our CYP2C19 ID kit, the second point of care pharmacogenetic test developed in collaboration with this team for NHS use, being made available for the benefit of patients who have suffered a stroke or TIA.”

Read the RNS: https://lnkd.in/e3_xqt3k

hashtag#GDR hashtag#POCT hashtag#pharmacogenomics hashtag#pharmacogenetics hashtag#diagnostics hashtag#medtech hashtag#pgxmovement hashtag#pointofcare hashtag#innovation hashtag#cyp2c19 hashtag#stroke hashtag#genetics hashtag#clopidogrel hashtag#patientsafety

@Bearded Dragon - Our SP is Rising on the back of Our Chairman - Dr Ian Gilham, Buying into Our Genedrive !!!

An NHS Implementation Plan - Is about them Buying Our CYP2C19 Test = Sales LOL

Perhaps this is a Good Time for You to Buy into Our GDR ?!!!

Our Chairman Dr Ian Gilham timed his purchase of an extra 1,000,000 shares at the cost of £31,000 having full view of the news to come !!

We do not know his reasoning in any certainty, But the Fact that he has chosen to Buy now (and Not sell), should tell us He believes there is Good News to come !!!

Ian Gilham could of bought these Extra 1,000,000 shares in the recent Fund raise at 1.5p, But he did not, and has chosen to Buy these Extra Shares Now, at more than Double the cost?!!! - ''WHY'' - News that has Now become More Certain, is my thoughts !!!

We can all guess at the News to come, But none of us actually know ?!!

I personally believe he bought Now, due to an Implementation Plan for the NHS using Our CYP2C19 POC (Bedside Test), in Large Volume across the UK ?!!! - And this News will be released Sooner rather than Later !!

Whatever the reason for his timely purchase - This is Great News !!!!

AIMHO

Some Good Buys yesterday after 4pm !!!

Date Time Trade Prc Volume Buy/Sell Bid Ask Value

14-Aug-24 16:29:36 3.10 750,000 Buy* 3.05 3.10 23.25k

14-Aug-24 16:29:09 3.10 1,000,000 Buy* 3.05 3.10 31.00k

14-Aug-24 16:25:47 3.105 655,172 Buy* 3.05 3.15 20.34k

14-Aug-24 16:19:30 3.10 100,000 Buy* 3.05 3.10 3,100

14-Aug-24 16:18:26 3.10 200,000 Buy* 3.05 3.10 6,200

14-Aug-24 16:18:04 3.10 67,613 Buy* 3.05 3.10 2,096

14-Aug-24 16:11:36 3.095 75,000 Sell* 3.05 3.15 2,321

14-Aug-24 16:10:12 3.119 500,000 Buy* 3.05 3.15 15.60k

14-Aug-24 16:04:09 3.105 29,000 Buy* 3.05 3.15 900.45

No Wonder Gino came over so Excited:-

bigAl67

Posts: 2,711

Price: 3.075

No Opinion

RE: List of posters who commit to emailing Walbrook?14 Aug 2024 23:13

Gino MieleGino Miele on Linkedin

• 2nd • 2nd

CEO / CSO, genedriveCEO / CSO, genedrive

6d • 6 days ago

Follow

I’m happy to share that I’m starting a new position as CEO at genedrive!

The above caption includes a picture of a Party ; a Cake, with a Cherry dropping onto the Cream on top of the Cake !!

Certainly Gino is Exceptionally Excited about his appointment !!!

I am looking forward to Gino sharing the Cake and the Cherry with us all !!! - And the Cream !!!

180 likes

85 comments:

Doris-Ann Williams MBE

Former Chief Executive at British In Vitro Diagnostics (retired Sept 2023)

4d

Congratulations on your new role at such an exciting time for the company - such great, innovative technology

85 comments:

Doris-Ann Williams MBE

Former Chief Executive at British In Vitro Diagnostics (retired Sept 2023)

4d

Congratulations on your new role at such an exciting time for the company - such great, innovative technology

Stephen Fletcher

CEO at Mantara Health Ltd | Personalised Medicine, Pharmacogenomics, Healthcare Operations, Pharmacy

6d

Congratulations Gino. Fantastic news.

Chris Yates

CEO of Abingdon Health Plc

6d

Many congratulations Gino, well deserved!

David Budd

Board | IVD | Diagnostics | Advisory | CEO | Medical Devices | Genetics | NED | Oncology | Interim | Medtech | Partnerships

(edited)

6d

Let’s ’ave ‘em!

Sanjay Shahi, PhD, MBA

Diagnostics Strategist | CDx, MDx, IVD, Genomics | Precision Medicine Implementation

6d

Congratulations! Gino.

Gino MieleGino Miele on Linkedin

• 2nd • 2nd

CEO / CSO, genedriveCEO / CSO, genedrive

6d • 6 days ago

Follow

I’m happy to share that I’m starting a new position as CEO at genedrive!

The above caption includes a picture of a Party ; a Cake, with a Cherry dropping onto the Cream on top of the Cake !!

Certainly Gino is Exceptionally Excited about his appointment !!!

I am looking forward to Gino sharing the Cake and the Cherry with us all !!!

180 likes

From Lionels Post: - And NICE Recommended Our Genedrive Point of Care (Bedside Test) CYP2C19 as the Preferred Point of Choice above the Genomadix Cube !!

Strokes are a leading cause of adult disability in the US, Schwartz said, so the ability to prevent them in patients presenting with TIA is crucial.

Stuart Scott, director of Stanford's Clinical Genomics Laboratory, said that Schwartz first proposed instituting CYP2C19 testing almost two years ago.

"It took us some time to think through the trends and the platform, but that ultimately led us to Genomadix last summer when the FDA approved their instrument," Scott said.

Although Stanford's neurologists have had access to genetic testing prior to this, ordering a 2C19 test from an outside lab could take weeks.

"That's not particularly helpful because this high-risk period is a few days to a few weeks, so we really would like to get that result within hours to help make this decision," said Schwartz.

Our UK Clinicians will want results in hours - Not days Too !!!

LOL Ms GloriaMarket - You posted today at 16:21:-

GloriaMarket

Posts: 2,541

Price: 3.55

No Opinion

RE: Hold for goldToday 18:21

''Did anyone hear about Elon Musk, glaxo and astrzeneca and whether they are all in a bidding war for GDR?''

''They've all been mentioned today on this chat board. Wierd?''

- Well what is Weird is that You started the below Thread, and then You Post quoting Musk; Glaxo and AstraZeneca are all in a bidding war - This is Desperate TROLL work by You Ms GloriaMarket - QED

You were the Poster that started this Weird connection, as ''YOU'' call it ?!!

YOU were the first to mention Elon Musk buying GDR - When you started the 'Musk to buy GDR' Thread - posted at 16:09: -

GloriaMarket

Posts: 2,541

Price: 3.425

No Opinion

Musk to buy GDR?Today 16:09

Could it be true that Elon Musk is interested in buying GDR?

Then After your post at 16:09 - Systemzero followed up 'on your same Thread' and quoted someone's post on ADVFN:-

Systemzero

Posts: 4,288

Price: 3.45

Strong Buy

RE: Musk to buy GDR?Today 16:15

On advf board they saying glaxo going to make offer of 15p.....probly bull...but you never know..!!

Then still on your same Thread - Muminr posted at 16:19, and gave a reason behind his post:-

Muminr

Posts: 184

Price: 3.475

No Opinion

RE: Musk to buy GDR?Today 16:19

I had always thought it’d make sense for Astra Zeneca to buy because they make the alternative to clopidogrel. Brilique costs £54.60 a month. That’s huge profits for them for every patient swapped.

Opps - meant to say:- Looks to have been an Admin error, which was corrected to 41,791 Buy Trade !

''417k trade was cancelled at 16:27:18''

Looks to have been an Admin error, which was corrected to 41,791k Buy Trade !

A while a go now, our Genedrive did say that they have in the past offered to supply our Machines without the user having to pay up front for them.

Instead users would pay an extra few quid for each Test to cover the cost of using our Machines.

I am not sure of the Product, but I think it was with regards to our MT-RNR1 Kit - and I also believe it was said that it is down to the negotiating GDR Sales person to decide on the financing process?!!

Should read:- ''the NHS wanted a faster Test result than the NHS Labs can supply?''

NICE Recommendation:-

There are likely to be considerable barriers to implementing laboratory-based testing for everyone who has had an ischaemic stroke or TIA. If laboratory-based testing is not available, or it will take a long time to develop capacity to provide it, then point-of-care tests could be used. So, the Genedrive CYP2C19 ID Kit should be used when laboratory-based testing is not available. ''

The above statement by NICE says that NICE know of the problem the Labs have in providing Test results in a timely manner.

Indeed it was the NHS that approached, and assisted our Genedrive to develop our CYP2C19 POC (Bedside Test), and this is because the NHS wanted a faster Test result that the NHS Labs can supply?

I believe that NICE would not want to place our Test as a first point of call, in front of the Lab Tests procedures, because of the retaliation this might bring from the Labs ?

Therefore to say that the Labs is the preferred procedure selected by NICE, followed by :- If laboratory-based testing is not available, or it will take a long time to develop capacity to provide it, then point-of-care tests could be used. So, the Genedrive CYP2C19 ID Kit should be used when laboratory-based testing is not available. '' - is in my opinion a more diplomatic approach ?!! IMHO

James Cheek taking an opportunity to get Our Genedrive further noticed ? - To the Minister for patient safety, Baroness Gillian Merron, who visited Guy's and St Thomas'​ NHS Foundation Trust with Patient Safety Commissioner Henrietta Hughes.

Plus 48 high level reactions to the Ministers visit at GST !!!

Department of Health and Social CareDepartment of Health and Social Care

273,995 followers273,995 followers

1d • 1 day ago

Follow

hashtag#MedTech has the potential to improve patients’ experience of healthcare and support a healthier population. It also provides an opportunity to directly boost employment across the UK, allowing for economic growth.

Minister for patient safety, Baroness Gillian Merron, visited Guy's and St Thomas'​ NHS Foundation Trust with Patient Safety Commissioner Henrietta Hughes.

Together they learnt about how med tech is being used at Guy’s and St Thomas’ to increase patient safety.

James CheekView James Cheek’s profile

• 3rd+

CEO / Country Manager / Director - highly commercial, collaborative leader who builds and leads result focused high performance teams. With experience in sales, operations, sourcing, tenders and strategy.

4:59:39 PM

Are GST using the antibiotic induced hearing loss, point of care, genetic test from Genedrive for neonates - preventing clinicians prescribing Gentamicin that can cause profound hearing loss and as such improve patient safety by saving a babies hearing and save the NHS money?